CYAD — Celyad Oncology SA Share News
0.000.00%
Last trade - 00:00- €9.93m
- €9.80m
- €0.02m
Brief: Celyad Oncology Presents Preclinical Data On Allogeneic Car T Therapy Program
Brief: Celyad Oncology End-Sept Cash At 6.1 Million Euros
Refile: BRIEF-Celyad Oncology Had EUR 12.0 Mln In Cash And Cash Equivalents At End-June
Brief: Celyad Oncology Updates On Allogeneic CAR T Clinical Candidates And shRNA-Based Preclinical Concepts
Brief: Celyad Oncology: Preliminary Data From IMMUNICY-1 trial of CYAD-211
Europe Research Roundup: Elis SA, Experian, Nokia Oyj
Brief: Celyad Oncology: CYAD-211 Phase 1 Immunicy-1 Trial Data
Brief: Celyad Oncology - As Of March 31, 2021, Co Had Cash And Cash Equivalents Of EUR 12.2 Million ($14.3 Million)
Brief: Celyad Oncology Appoints Charles Morris As Chief Medical Officer
Brief: Celyad Oncology Says FY Loss Per Share EUR 1.23
Brief: Celyad Oncology Presents Data Update From Phase 1 alloSHRINK Trial For CYAD-101 In mCRC
Brief: Celyad Oncology Signs Equity Purchase Agreement With Lincoln Park Capital
Brief: Celyad Oncology Provides Updates On CYAD-211, CYAD-01 And CYAD-02
Brief: Celyad Oncology Announces Dosing Of First Patient In Phase 1 Immunicy-1 Trial Of Cyad-211
Brief: Celyad Oncology Announces Third Quarter 2020 Financial Results And Recent Business Highlights
Brief: Celyad Oncology Announces Clinical Trial Collaboration With MSD
Brief: Celyad Oncology To Sell Up to $25 Mln Of New American Depositary Shares
Brief: Celyad Oncology Files For Mixed Shelf Of Up To $250 Million
Brief: Celyad Oncology Announces FDA Clearance Of IND Application For CYAD-211